表紙
市場調査レポート

Eslicarbazepine acetate(神経障害性疼痛)- 予測と市場分析

Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 302376
出版日 ページ情報 英文 87 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Eslicarbazepine acetate(神経障害性疼痛)- 予測と市場分析 Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022
出版日: 2014年04月30日 ページ情報: 英文 87 Pages
概要

神経障害性疼痛(NP)は感覚運動系の障害として定義され、侵害受容性疼痛(外傷・傷害・炎症によって生じる疼痛)とは厳密に区分されています。神経障害性疼痛と侵害受容性疼痛の主な違いは、神経障害性疼痛には持続的な侵害受容が無いことが挙げられます。神経障害性疼痛(NP)の3大適応症(疼痛を伴う糖尿病性神経障害、帯状疱疹後神経痛、三叉神経痛)の治療で使用される主要な薬剤クラスには、抗けいれん薬、抗うつ薬、オピオイド、局所療法などが含まれます。しかし、複数の鎮痛薬が利用できるにもかかわらず、患者の50%にしか有効でなく、多数の副作用によって、忍容性が低くなっています。

当レポートでは、神経障害性疼痛(NP)の治療薬であるEslicarbazepine acetateについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 臨床症状 - 兆候と症状
    • 疼痛を伴う糖尿病性神経障害
    • 帯状疱疹後神経痛
    • 三叉神経痛
  • 病因・病態生理
    • 病因
    • 病態生理

第4章 疾病の管理

  • 診断と治療の概要
    • 診断
    • 治療の概要とガイドライン

第5章 競合評価

  • 概要

第6章 アンメットニーズと機会

  • 概要
  • 医師の知識または意識
  • 診断の課題
  • 低い治療率と過小量投与
  • 薬物治療の不満足な有効性と安全性プロファイル
  • 高齢患者人口 - 薬物忍容性
  • 合理的/個人的な治療

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 Eslicarbazepine Acetate

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的/商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC408DFR

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Eslicarbazepine acetate is a drug that was developed by Bial-Portela & Ca., and is currently in Phase III of clinical development for PDN and PHN. It has already been approved for marketing in Europe and the US for the adjunctive treatment of adults with partial epileptic seizures. It was launched in the EU by Bial in conjunction with Eisai in 2009, and received FDA approval in the US in November 2013, where it is being developed and commercialized by Sunovion Pharmaceuticals under the brand name Aptiom.

Scope

  • Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Eslicarbazepine acetate including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Eslicarbazepine acetate for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Eslicarbazepine acetate performance
  • Obtain sales forecast for Eslicarbazepine acetate from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Clinical Manifestations of Neuropathic Pain - Signs and Symptoms
    • 3.1.1. Painful Diabetic Neuropathy
    • 3.1.2. Postherpetic Neuralgia
    • 3.1.3. Trigeminal Neuralgia
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Overview and Guidelines

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Physician Knowledge or Awareness
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Diagnostic Challenges
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Low Treatment Rate and Underdosing of Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Elderly Patient Population - Drug Tolerability
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Rational or Personalized Therapies
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Eslicarbazepine Acetate

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. Pricing and Reimbursement
  • 8.7. SWOT Analysis
  • 8.8. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed PDN, PHN, and TN Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage
  • Table 2: Signs and Symptoms of NP
  • Table 3: Screening Tools for NP
  • Table 4: NP-Related Signs and Symptoms
  • Table 5: Treatment Guidelines for NP
  • Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy
  • Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012
  • Table 8: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013
  • Table 9: Select Products Used for NP Treatment, 2013
  • Table 10: Unmet Need and Opportunity in NP
  • Table 11: NP - Promising Drugs in Clinical Development
  • Table 12: Comparison of Drugs in Development for NP, 2014
  • Table 13: Product Profile - Eslicarbazepine Acetate
  • Table 14: Phase II: Efficacy of Eslicarbazepine Acetate in PHN
  • Table 15: Phase II: Efficacy of Eslicarbazepine Acetate in PDN
  • Table 16: Eslicarbazepine Acetate SWOT Analysis, 2013
  • Table 17: Global Sales Forecasts ($m) for Eslicarbazepine Acetate, 2012-2022

List of Figures

  • Figure 1: Nociceptive Versus Neuropathic Pain
  • Figure 2: Etiology and Pathophysiology of NP
  • Figure 3: Pain Pathway - Somatosensory System
  • Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System
  • Figure 5: Pathophysiological Targets of NP Drugs
  • Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP
  • Figure 7: General Treatment Algorithm for NP
  • Figure 8: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022
Back to Top